Caseware UK (AP4) 2022.0.179 2022.0.179 2023-04-302023-04-30false2022-05-01No description of principal activity2019truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 11923594 2022-05-01 2023-04-30 11923594 2021-05-01 2022-04-30 11923594 2023-04-30 11923594 2022-04-30 11923594 c:Director1 2022-05-01 2023-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2022-05-01 2023-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2023-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2022-04-30 11923594 d:PlantMachinery 2022-05-01 2023-04-30 11923594 d:PlantMachinery 2023-04-30 11923594 d:PlantMachinery 2022-04-30 11923594 d:PlantMachinery d:OwnedOrFreeholdAssets 2022-05-01 2023-04-30 11923594 d:MotorVehicles 2022-05-01 2023-04-30 11923594 d:MotorVehicles 2023-04-30 11923594 d:MotorVehicles 2022-04-30 11923594 d:MotorVehicles d:OwnedOrFreeholdAssets 2022-05-01 2023-04-30 11923594 d:FurnitureFittings 2022-05-01 2023-04-30 11923594 d:FurnitureFittings 2023-04-30 11923594 d:FurnitureFittings 2022-04-30 11923594 d:FurnitureFittings d:OwnedOrFreeholdAssets 2022-05-01 2023-04-30 11923594 d:OwnedOrFreeholdAssets 2022-05-01 2023-04-30 11923594 d:CurrentFinancialInstruments 2023-04-30 11923594 d:CurrentFinancialInstruments 2022-04-30 11923594 d:Non-currentFinancialInstruments 2023-04-30 11923594 d:Non-currentFinancialInstruments 2022-04-30 11923594 d:CurrentFinancialInstruments d:WithinOneYear 2023-04-30 11923594 d:CurrentFinancialInstruments d:WithinOneYear 2022-04-30 11923594 d:Non-currentFinancialInstruments d:AfterOneYear 2023-04-30 11923594 d:Non-currentFinancialInstruments d:AfterOneYear 2022-04-30 11923594 d:ShareCapital 2023-04-30 11923594 d:ShareCapital 2022-04-30 11923594 d:RetainedEarningsAccumulatedLosses 2023-04-30 11923594 d:RetainedEarningsAccumulatedLosses 2022-04-30 11923594 c:FRS102 2022-05-01 2023-04-30 11923594 c:AuditExempt-NoAccountantsReport 2022-05-01 2023-04-30 11923594 c:FullAccounts 2022-05-01 2023-04-30 11923594 c:PrivateLimitedCompanyLtd 2022-05-01 2023-04-30 iso4217:GBP xbrli:pure

Registered number: 11923594









WEELSBY VIEW PHARMACY LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2023

 
WEELSBY VIEW PHARMACY LTD
 
 
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 30 APRIL 2023

2023
2022
£
£

  

Turnover
  
2,405,006
1,573,430

Cost of sales
  
(1,445,256)
(1,017,542)

Gross profit
  
959,750
555,888

Administrative expenses
  
(582,128)
(345,363)

Other operating income
  
-
802

Operating profit
  
377,622
211,327

Tax on profit
  
(42,641)
(39,868)

Profit for the financial year
  
334,981
171,459

Page 1

 
WEELSBY VIEW PHARMACY LTD
REGISTERED NUMBER: 11923594

BALANCE SHEET
AS AT 30 APRIL 2023

2023
2022
£
£

Fixed assets
  

Tangible assets
 4 
349,767
256,100

  
349,767
256,100

Current assets
  

Stocks
 5 
154,068
145,201

Debtors: amounts falling due within one year
 6 
223,987
200,799

Cash at bank and in hand
 7 
298,440
79,127

  
676,495
425,127

Creditors: amounts falling due within one year
 8 
(214,733)
(187,995)

Net current assets
  
 
 
461,762
 
 
237,132

Total assets less current liabilities
  
811,529
493,232

Creditors: amounts falling due after more than one year
 9 
-
(16,684)

  

Net assets
  
811,529
476,548


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
811,429
476,448

  
811,529
476,548


Page 2

 
WEELSBY VIEW PHARMACY LTD
REGISTERED NUMBER: 11923594
    
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 6 November 2023.




Mr M Patel
Director

Page 3

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023

1.


General information

Weelsby View Pharmacy Ltd is a private company limited by shares. The company is incorporated in England & Wales and its registered office address is Aston House, Cornwall Avenue, London, N3 1LF. The registered number is 11923594.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 4

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023

2.Accounting policies (continued)

 
2.3

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of income and retained earnings in the same period as the related expenditure.

  
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income ot to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.
The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in United Kingdom. 

 
2.5

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 5

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023

2.Accounting policies (continued)


2.6
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Long-term leasehold property
-
Straight Line Method for 8 years
Plant and machinery
-
25%
Reducing Balance Method
Motor vehicles
-
25%
Reducing Balance Method
Fixtures and fittings
-
25%
Reducing Balance Method

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.11

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
Page 6

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023

2.Accounting policies (continued)


2.11
Financial instruments (continued)



3.


Employees

The average monthly number of employees, including directors, during the year was 20 (2022 - 19).


4.


Tangible fixed assets





Long-term leasehold property
Plant and machinery
Motor vehicles
Fixtures and fittings
Total

£
£
£
£
£



Cost or valuation


At 1 May 2022
242,989
-
7,079
43,350
293,418


Additions
-
157,211
-
3,759
160,970



At 30 April 2023

242,989
157,211
7,079
47,109
454,388



Depreciation


At 1 May 2022
30,374
-
442
6,503
37,319


Charge for the year on owned assets
30,375
26,056
1,659
9,212
67,302



At 30 April 2023

60,749
26,056
2,101
15,715
104,621



Net book value



At 30 April 2023
182,240
131,155
4,978
31,394
349,767



At 30 April 2022
212,615
-
6,637
36,848
256,100


5.


Stocks

2023
2022
£
£

Finished goods and goods for resale
154,068
145,201

154,068
145,201


Page 7

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2023

6.


Debtors

2023
2022
£
£


Amounts owed by group undertakings
20,000
20,000

Other debtors
202,241
180,799

Prepayments and accrued income
1,746
-

223,987
200,799



7.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
298,438
79,127

298,438
79,127



8.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
149,437
143,127

Corporation tax
42,641
39,868

Other taxation and social security
5,595
-

Other creditors
11,265
-

Accruals and deferred income
5,795
5,000

214,733
187,995



9.


Creditors: Amounts falling due after more than one year

2023
2022
£
£

Amounts owed to group undertakings
-
16,684

-
16,684


 
Page 8